• Exclusive distributor rights for Curaleaf's certified medicinal cannabis inhaler and cartridges in Australia
• Nationwide distribution from November 2025 across prescribers and pharmacies
• Strong revenue contribution expected, supporting Bioxyne's FY26 guidance

Bioxyne Limited (ASX: BXN), through its subsidiary Breathe Life Sciences (BLS), has executed an exclusive import, manufacture and supply agreement with Curaleaf International for the Que Medical Inhalation Device (QMID) in Australia. Following import approval notification by the Therapeutic Goods Administration (TGA) on 1 October 2025 and authorization by the Office of Drug Control to import on 27 October, BLS plans to launch the QMID in Australia in November 2025, making it available via authorized prescribers, Special Access Scheme-Category B and pharmacies nationwide. The QMID is the first EU Class IIa medical device for use with medical cannabis liquid inhalants, a key differentiator from other liquid dose form inhalation products on the market. Under the agreement, BLS has exclusive rights to import, manufacture (including active pharmaceutical ingredients and device filling) and distribute Curaleaf's certified medicinal cannabis inhaler and cartridges in Australia. This collaboration represents an important step in expanding access to regulated, medically compliant inhalation technology in Australia and strengthens Bioxyne's position within the medical device sector.

This agreement is expected to add a new recurring revenue stream (device + replacement cartridges) that supports Bioxyne's FY26 guidance of revenue $65m - $75m and EBITDA of $11.5m - $13.5m.

The launch of the QMID in Australia is part of Curaleaf International's wider mission to develop innovative medical technologies that support healthcare professionals in the delivery of treatment. The QMID is designed as a discreet and reliable inhalation device which, together with Bioxyne, can now be offered to eligible patients in Australia.